Search Results - "GILBERT, P. B."

COVID-19 vaccine trials should seek worthwhile efficacy by Krause, Philip, Fleming, Thomas R, Longini, Ira, Henao-Restrepo, Ana Maria, Peto, Richard, Dean, NE, Halloran, ME, Huang, Y, Fleming, TR, Gilbert, PB, DeGruttola, V, Janes, HE, Krause, PR, Longini, IM, Nason, MC, Peto, R, Smith, PG, Riveros, AX, Gsell, PS, Henao-Restrepo, AM

“…[...]the initial trials comparing COVID-19 vaccines versus placebo should seek reliable evidence not only of some efficacy but of worthwhile efficacy…”
Get full text

Mark‐Specific Hazard Ratio Model with Multivariate Continuous Marks: An Application to Vaccine Efficacy by Juraska, M, Gilbert, P. B

“…: In randomized placebo‐controlled preventive HIV vaccine efficacy trials, an objective is to evaluate the relationship between vaccine efficacy to prevent…”
Get full text

Analysis-Based Design Provisions for Steel Storage Racks by Rasmussen, K. J. R, Gilbert, B. P

“…AbstractThe paper summarizes the main new design provisions included in the recently revised Australian standard for steel storage racks. The standard features…”
Get full text

Doubly robust nonparametric inference on the average treatment effect by BENKESER, D., CARONE, M., VAN DER LAAN, M. J., GILBERT, P. B.

“…Doubly robust estimators are widely used to draw inference about the average effect of a treatment. Such estimators are consistent for the effect of interest…”
Get full text

A study of vaccine-induced immune pressure on breakthrough infections in the Phambili phase 2b HIV-1 vaccine efficacy trial by Hertz, T, Logan, M.G, Rolland, M, Magaret, C.A, Rademeyer, C, Fiore-Gartland, A, Edlefsen, P.T, DeCamp, A, Ahmed, H, Ngandu, N, Larsen, B.B, Frahm, N, Marais, J, Thebus, R, Geraghty, D, Hural, J, Corey, L, Kublin, J, Gray, G, McElrath, M.J, Mullins, J.I, Gilbert, P.B, Williamson, C

“…Abstract Introduction The Merck Adenovirus-5 Gag/Pol/Nef HIV-1 subtype-B vaccine evaluated in predominately subtype B epidemic regions (Step Study), while not…”
Get full text

Experimental collapse response of post-and-beam mass timber frames under a quasi-static column removal scenario by Lyu, C.H., Gilbert, B.P., Guan, H., Underhill, I.D., Gunalan, S., Karampour, H., Masaeli, M.

“…•Ability of post-and-beam timber frames to resist progressive collapse was studied.•Compressive arch and catenary actions under large deformations were…”
Get full text

Long-term safety analysis of preventive HIV-1 vaccines evaluated in AIDS vaccine evaluation group NIAID-sponsored Phase I and II clinical trials by Gilbert, P.B., Chiu, Y.-L., Allen, M., Lawrence, D.N., Chapdu, C., Israel, H., Holman, D., Keefer, M.C., Wolff, M., Frey, S.E.

“…This report evaluates long-term safety data from 3189 human immunodeficiency virus type 1 (HIV-1) uninfected, healthy volunteers who were enrolled into 51…”
Get full text

General regression model for the subdistribution of a competing risk under left-truncation and right-censoring by Bellach, A, Kosorok, M R, Gilbert, P B, Fine, J P

“…Summary Left-truncation poses extra challenges for the analysis of complex time-to-event data. We propose a general semiparametric regression model for…”
Get full text

Experimental study on the quasi-static progressive collapse response of post-and-beam mass timber buildings under an edge column removal scenario by Lyu, C.H., Gilbert, B.P., Guan, H., Underhill, I.D., Gunalan, S., Karampour, H.

“…•3D mass timber substructures were tested under an edge column removal scenario.•The applied load was mainly transferred to the three nearest columns.•CLT…”
Get full text

Experimental study on the quasi-static progressive collapse response of post-and-beam mass timber buildings under corner column removal scenarios by Lyu, C.H., Gilbert, B.P., Guan, H., Underhill, I.D., Gunalan, S., Karampour, H.

“…•3D post-and-beam mass timber substructures were tested against progressive collapse.•Tests were performed under different corner column removal scenarios.•The…”
Get full text

OA06-06 LB. Evidence of vaccine-induced changes in breakthrough HIV-1 strains from the Step trial by Rolland, M, Tovanabutra, S, Gilbert, PB, Sanders-Buell, E, Heath, L, deCamp, AC, Magaret, CC, Bose, M, Bradfield, A, O'Sullivan, A, Crossler, J, Deng, W, Zhao, H, Wong, K, Raugi, DN, Hural, J, Dubey, S, Frahm, N, Michael, NL, Shiver, J, Corey, L, Li, F, Self, SG, Kim, J, Buchbinder, S, Casimiro, DR, Robertson, MN, McElrath, MJ, McCutchan, FE, Mullins, JI

“…[...] ~10 AA signature sites in Gag, Nef, Pol (but none in Env) were found to classify vaccine versus placebo status…”
Get full text

Maximum likelihood estimation in semiparametric selection bias models with application to AIDS vaccine trials by Gilbert, PB, Lele, SR, Vardi, Y

“…The following problem is treated: given s possibly selection biased samples from an unknown distribution function, and assuming that the sampling rule weight…”
Get full text

Scaling effect on the moment and shear responses of three types of beam-to-column connectors used in mass timber buildings by Masaeli, M., Gilbert, B.P., Karampour, H., Underhill, I.D., Lyu, C.H., Gunalan, S.

“…•Scaling effect investigated on timber beam-to-column connections.•Full-scale and ¼-scale down connections showed similar failure modes.•Full-scale and ¼-scale…”
Get full text

A cluster of tuberculosis among crack house contacts in San Mateo County, California by Leonhardt, K K, Gentile, F, Gilbert, B P, Aiken, M

“…In March 1992, a cluster of 89 persons with tuberculosis infection was identified in San Mateo County, California. Thirteen persons (15%), including 11…”
Get full text

Correlation between Immunologic Responses to a Recombinant Glycoprotein 120 Vaccine and Incidence of HIV-1 Infection in a Phase 3 HIV-1 Preventive Vaccine Trial by Gilbert, Peter B., Peterson, Michael L., Follmann, Dean, Hudgens, Michael G., Francis, Donald P., Gurwith, Marc, Heyward, William L., Jobes, David V., Popovic, Vladimir, Self, Steven G., Sinangil, Faruk, Burke, Donald, Berman, Phillip W.

“…BackgroundAn objective of the first efficacy trial of a candidate vaccine containing recombinant human immunodeficiency virus (HIV) type 1 envelope…”
Get full text

Allospecific CD154 + T-cytotoxic memory cells as potential surrogate for rejection risk in pediatric intestine transplantation by Sindhi, Rakesh, Ashokkumar, Chethan, Higgs, Brandon W., Gilbert, P. B., Sun, Qing, Ranganathan, Sarangarajan, Jaffe, Ron, Snyder, Sara, Ningappa, Mylarappa, Soltys, Kyle A., Bond, Geoffrey J., Mazariegos, George V., Abu-Elmagd, Kareem, Zeevi, Adriana

“…Sindhi R, Ashokkumar C, Higgs BW, Gilbert PB, Sun Q, Ranganathan S, Jaffe R, Snyder S, Ningappa M, Soltys KA, Bond GJ, Mazariegos GV, Abu‐Elmagd K, Zeevi A…”
Get full text

Capacity of innovative nailplated joints subjected to accelerated moisture cycling by Mainey, A. J., Gilbert, B. P., Bailleres, H., Gunalan, S., Smith, M. D.

“…Nailplated timber trusses are widely used in residential housing. However, there is limited evidence of use or research on the application of nailplated…”
Get full text

Assessing variable importance in survival analysis using machine learning by Wolock, C J, Gilbert, P B, Simon, N, Carone, M

“…Given a collection of features available for inclusion in a predictive model, it may be of interest to quantify the relative importance of a subset of features…”
Get full text

Comparison of HIV-1 and HIV-2 infectivity from a prospective cohort study in Senegal by Gilbert, Peter B., McKeague, Ian W., Eisen, Geoffrey, Mullins, Christopher, Guéye-NDiaye, Aissatou, Mboup, Souleymane, Kanki, Phyllis J.

“…From a prospective cohort study of 1948 initially human immunodeficiency virus (HIV) uninfected female commercial sex workers followed between 1985 and 1999 in…”
Get full text

HIV-1 Virologic and Immunologic Progression and Initiation of Antiretroviral Therapy among HIV-1–Infected Subjects in a Trial of the Efficacy of Recombinant Glycoprotein 120 Vaccine by Gilbert, Peter B., Ackers, Marta L., Berman, Phillip W., Francis, Donald P., Popovic, Vladimir, Hu, Dale J., Heyward, William L., Sinangil, Faruk, Shepherd, Bryan E., Gurwith, Marc

“…The first trial of the efficacy of a human immunodeficiency virus (HIV)–1 vaccine was conducted in North America and The Netherlands between 1998 and 2003…”
Get full text